Susquehanna International Group, LLP Atea Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.17 - $4.02 $260,574 - $330,443	-82,200 Reduced 45.79%	97,300 $325,000
Q2 2024 Aug 15, 2024	SELL	$3.31 - $4.04 $16,550 - $20,200	-5,000 Reduced 2.71%	179,500 $594,000
Q1 2024 May 07, 2024	BUY	$3.09 - $4.56 $479,259 - $707,255	155,100 Added 527.55%	184,500 $745,000
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $82,320 - $98,490	29,400 New	29,400 $89,000
Q2 2023 Aug 11, 2023	BUY	$3.21 - $5.06 $108,498 - $171,028	33,800 New	33,800 $126,000
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $74,820 - $106,124	-17,200 Reduced 41.25%	24,500 $117,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $32,391 - $51,860	5,900 Added 16.48%	41,700 $237,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $283M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.